Oral Small Molecule Therapeutics
•254 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (254)
| Company | Market Cap | Price |
|---|---|---|
|
ABUS
Arbutus Biopharma Corporation
AB-101 is described as an oral small-molecule PD-L1 inhibitor, representing an oral small molecule therapeutics product line.
|
$845.39M |
$4.43
+2.55%
|
|
ESPR
Esperion Therapeutics, Inc.
Oral small-molecule LDL-C lowering therapies (NEXLETOL/NEXLIZET).
|
$796.41M |
$3.96
+7.18%
|
|
ALMS
Alumis Inc. Common Stock
Alumis is developing oral TYK2 inhibitors (ESK-001 and A-005), a major product category of oral small molecule therapeutics.
|
$795.05M |
$7.65
+4.37%
|
|
GOSS
Gossamer Bio, Inc.
Seralutinib is a small molecule therapeutic, classifying under small molecule therapeutics in the existing taxonomy.
|
$759.45M |
$3.35
+2.45%
|
|
GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics develops and commercializes small-molecule therapeutics (lead Hydronidone/F351 and multiple pipeline agents, plus licensed products) for fibrotic diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$756.06M |
$7.86
+1.75%
|
|
CRMD
CorMedix Inc.
MINOCIN is an oral small-molecule antibiotic, reflecting an oral antibiotic product line.
|
$720.36M |
$9.65
+2.66%
|
|
VTYX
Ventyx Biosciences, Inc.
VTX assets are oral small molecule therapeutics for autoimmune/inflammatory diseases (NLRP3 inhibitors).
|
$712.37M |
$10.00
-4.40%
|
|
KALV
KalVista Pharmaceuticals, Inc.
EKTERLY (sebetralstat) is KalVista's lead asset and is an oral small-molecule therapeutic for acute hereditary angioedema, directly reflecting their product category.
|
$704.35M |
$14.11
+6.25%
|
|
CGEM
Cullinan Therapeutics, Inc.
Zipalertinib is an orally administered small-molecule EGFR inhibitor targeting ex20ins NSCLC.
|
$693.53M |
$11.74
-0.42%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Soquelitinib is an orally bioavailable small molecule therapeutic, classifying the program under Oral Small Molecule Therapeutics.
|
$675.84M |
$9.06
+2.20%
|
|
OMER
Omeros Corporation
Pipeline includes oral small-molecule therapeutics in addition to biologics.
|
$655.38M |
$9.63
+1.90%
|
|
VSTM
Verastem, Inc.
Lead products are oral small-molecule inhibitors (avutometinib, defactinib) used in combination therapy, fitting the 'Oral Small Molecule Therapeutics' category.
|
$654.23M |
$10.63
+3.76%
|
|
AQST
Aquestive Therapeutics, Inc.
Anaphylm's oral small-molecule epinephrine film and AQST-108 (epinephrine topical gel) indicate a focus on oral small-molecule therapeutics delivered via film/topical formats.
|
$620.28M |
$6.21
+1.97%
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$612.32M |
$11.32
-1.91%
|
|
RAPT
RAPT Therapeutics, Inc.
Tivumecirnon is an oral small-molecule CCR4 antagonist, aligning with Oral Small Molecule Therapeutics.
|
$550.05M |
$33.26
+10.98%
|
|
MNPR
Monopar Therapeutics Inc.
ALXN1840 is an oral small-molecule therapeutic for Wilson disease, aligning with Oral Small Molecule Therapeutics.
|
$539.01M |
$87.19
-1.45%
|
|
DSGN
Design Therapeutics, Inc.
Company develops small-molecule therapeutics (GeneTAC) targeting inherited nucleotide repeat disorders.
|
$533.60M |
$9.40
-0.11%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$519.66M |
$1.44
+1.77%
|
|
ZVRA
Zevra Therapeutics, Inc.
KP1077 and OLPRUVA are oral small molecule therapies (prodrugs); Zevra's pipeline includes oral small-molecule therapeutics.
|
$482.76M |
$8.60
+2.32%
|
|
ANNX
Annexon, Inc.
ANX1502 is an oral small molecule inhibitor, categorized under Oral Small Molecule Therapeutics.
|
$474.71M |
$4.32
-2.82%
|
|
ETON
Eton Pharmaceuticals, Inc.
KHINDIVI (ET-400), ET-600, ET-700, and ET-800 involve oral/ready formulations (e.g., desmopressin, hydrocortisone, zinc) consistent with the Oral Small Molecule Therapeutics category.
|
$434.18M |
$16.20
-0.46%
|
|
SIGA
SIGA Technologies, Inc.
TPOXX is available in an oral formulation, placing SIGA in the Oral Small Molecule Therapeutics category.
|
$432.50M |
$6.05
+1.68%
|
|
AKBA
Akebia Therapeutics, Inc.
Vafseo (vadadustat) is Akebia's core product, an oral small-molecule therapeutic (HIF-PHI) for CKD anemia, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$421.58M |
$1.59
+1.27%
|
|
PRTC
PureTech Health plc
LYT-100 is an oral small-molecule therapeutic for IPF.
|
$412.68M |
N/A
|
|
ITOS
iTeos Therapeutics, Inc.
EOS-984 ENT1 inhibitor and other small-molecule assets indicate development or use of oral small molecule therapeutics.
|
$388.48M |
$10.15
|
|
VIGL
Vigil Neuroscience, Inc.
VG-3927 is an oral small molecule TREM2 agonist, placing Vigil's small-molecule therapeutic program under Oral Small Molecule Therapeutics.
|
$375.71M |
$8.05
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Navacaprant is an oral small-molecule therapeutic, aligning with Oral Small Molecule Therapeutics.
|
$370.86M |
$2.30
+2.22%
|
|
GALT
Galectin Therapeutics Inc.
The company is pursuing a small molecule oral galectin-3 inhibitor program via Galectin Sciences LLC, representing an Oral Small Molecule Therapeutics pathway.
|
$368.99M |
$5.75
+0.70%
|
|
ANRO
Alto Neuroscience, Inc.
ALTO-300 is an oral small molecule therapeutic (melatonin receptor agonist/5-HT2C antagonist), a major product category.
|
$365.81M |
$13.56
+1.50%
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$335.20M |
$9.34
+3.72%
|
|
ALDX
Aldeyra Therapeutics, Inc.
ADX-629 is an oral RASP modulator, classed as oral small molecule therapeutics.
|
$334.82M |
$5.59
+6.27%
|
|
AMRN
Amarin Corporation plc
Icosapent ethyl is administered orally as a lipid-lowering therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$331.95M |
$16.09
+2.35%
|
|
AVXL
Anavex Life Sciences Corp.
Company's lead product and pipeline consist of oral small-molecule therapeutics (ANAVEX 2-73 and ANAVEX 3-71).
|
$331.55M |
$3.87
+11.85%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$313.17M |
$5.31
+6.20%
|
|
ACRS
Aclaris Therapeutics, Inc.
ATI-2138 is an oral small-molecule therapeutic (ITK/JAK3 inhibitor), aligning with Oral Small Molecule Therapeutics.
|
$312.00M |
$2.90
+6.23%
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Lead programs are oral small-molecule therapeutics targeting NI&I indications.
|
$301.73M |
$10.77
+0.56%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Lead RSV programs (zelicapavir and EDP-323) are oral small-molecule therapeutics, aligning with the Oral Small Molecule Therapeutics theme.
|
$298.01M |
$13.94
+2.05%
|
|
DRUG
Bright Minds Biosciences Inc.
Developing small-molecule therapeutics (5-HT receptor agonists), a major drug class.
|
$295.33M |
$65.95
+0.64%
|
|
MREO
Mereo BioPharma Group plc
Alvelestat is an oral small-molecule therapeutic, aligning with Oral Small Molecule Therapeutics.
|
$292.74M |
$1.83
+2.51%
|
|
ACIU
AC Immune S.A.
Oral Small Molecule Therapeutics – Morphomer platform developing small-molecule inhibitors (e.g., Tau aggregation, alpha-synuclein) for neurodegeneration.
|
$292.53M |
$2.92
+0.69%
|
|
ASMB
Assembly Biosciences, Inc.
Pipeline products are administered orally, classifying the company under oral small-molecule therapeutics as a core product modality.
|
$285.33M |
$37.01
-1.10%
|
|
IMRX
Immuneering Corporation
Atebimetinib (IMM-1-104) is an oral small-molecule therapeutic in clinical trials.
|
$272.75M |
$7.51
+0.94%
|
|
FHTX
Foghorn Therapeutics Inc.
FHD-909 is a selective oral small-molecule inhibitor; pipeline includes additional oral small-molecule therapeutics.
|
$271.91M |
$4.82
+2.12%
|
|
PBYI
Puma Biotechnology, Inc.
Neratinib and alisertib are oral small-molecule therapeutics, indicating a major category of oral oncology drugs.
|
$254.37M |
$5.06
+2.22%
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$247.35M |
$4.84
+5.56%
|
|
AVIR
Atea Pharmaceuticals, Inc.
The company is developing an oral fixed-dose combination regimen of bemnifosbuvir and ruzasvir for HCV, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$242.04M |
$3.07
+1.32%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$241.40M |
$4.61
+4.30%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$230.25M |
$7.10
+1.72%
|
|
TNYA
Tenaya Therapeutics, Inc.
TN-301 is an oral small-molecule HDAC6 inhibitor, qualifying as Oral Small Molecule Therapeutics.
|
$221.65M |
$1.37
+11.38%
|
|
BDTX
Black Diamond Therapeutics, Inc.
BDTX-1535 is a brain-penetrant, fourth-generation EGFR inhibitor, representing an oral small molecule therapeutic.
|
$215.22M |
$3.77
-2.45%
|
|
AARD
Aardvark Therapeutics, Inc. Common Stock
ARD-101 and ARD-201 are oral small-molecule therapeutics targeting satiety pathways for metabolic and rare-disease indications.
|
$209.81M |
$9.67
+3.20%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$190.88M |
$7.83
-0.32%
|
|
CCCC
C4 Therapeutics, Inc.
Lead assets (e.g., cemsidomide) are orally bioavailable small-molecule degraders, fitting the 'Oral Small Molecule Therapeutics' category.
|
$190.74M |
$2.67
+7.86%
|
|
NTHI
NEONC TECHNOLOGIES HOLDINGS, INC.
NEO212 is an oral small molecule therapeutic being developed for brain tumors.
|
$164.29M |
$8.71
-1.47%
|
|
SAVA
Cassava Sciences, Inc.
Direct product category: simufilam is developed as an oral small-molecule therapeutic.
|
$163.76M |
$3.40
+11.68%
|
|
CRDF
Cardiff Oncology, Inc.
Onvansertib is an oral small-molecule therapeutic, representing the company's primary product modality.
|
$155.67M |
$2.33
+10.66%
|
|
NVCT
Nuvectis Pharma, Inc.
NXP900 is described with oral dosing (mg/day), supporting the tag 'Oral Small Molecule Therapeutics'.
|
$154.27M |
$6.07
-0.41%
|
|
SLS
SELLAS Life Sciences Group, Inc.
SLS009 (tambiciclib) is a small-molecule CDK9 inhibitor, qualifying as Oral Small Molecule Therapeutics.
|
$153.73M |
$1.46
+1.04%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
CRB-913 is an oral small molecule CB1 inverse agonist aimed at obesity; classifies as an oral small molecule therapeutic.
|
$145.59M |
$11.90
+4.71%
|
|
ACTU
Actuate Therapeutics Inc
Elraglusib includes oral tablet formulation development, aligning with the Oral Small Molecule Therapeutics category.
|
$143.14M |
$6.89
+10.24%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL is Tonix's lead oral small-molecule drug for fibromyalgia (cyclobenzaprine HCl sublingual), a direct product the company develops and plans to bring to market.
|
$132.19M |
$15.06
+7.00%
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$131.12M |
$2.33
-0.21%
|
|
IXHL
Incannex Healthcare Limited
Incannex develops oral small-molecule therapeutics as fixed-dose drug combinations (IHL-42X).
|
$124.17M |
$0.34
+1.23%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$121.23M |
$1.66
+13.36%
|
|
IKT
Inhibikase Therapeutics, Inc.
IKT's lead program IKT-001Pro is an oral small-molecule therapeutic prodrug, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$114.76M |
$1.54
-1.59%
|
|
GANX
Gain Therapeutics, Inc.
GT-02287 is a small-molecule therapeutic candidate, aligning with the major product category of oral small-molecule therapeutics.
|
$112.88M |
$3.15
+7.71%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$111.27M |
$6.29
+10.05%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Azenosertib is an oral small-molecule inhibitor, making this a direct major product category for the company.
|
$103.88M |
$1.45
+0.35%
|
|
CLNN
Clene Inc.
CNM-Au8 is the lead asset pursued as a therapeutic, likely administered orally as a small-molecule/low-molecular-weight product.
|
$101.40M |
$10.12
+7.14%
|
|
ATOS
Atossa Therapeutics, Inc.
Z-endoxifen is an oral small-molecule therapeutic, and Atossa is prioritizing its metastatic breast cancer indication, representing a major product category.
|
$100.73M |
$0.78
+1.61%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is an oral small molecule therapeutic for Alzheimer's disease.
|
$98.42M |
$6.08
-0.33%
|
|
PLRX
Pliant Therapeutics, Inc.
Company's lead and mid-stage assets include oral small-molecule therapeutics (bexotegrast and PLN-101095) targeting integrin pathways.
|
$96.99M |
$1.58
+0.64%
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Anebulo's lead candidate selonabant is a small molecule therapeutic (initially oral) targeting cannabis-induced CNS effects; thus aligns with Oral Small Molecule Therapeutics.
|
$96.14M |
$2.41
-3.21%
|
|
ANVS
Annovis Bio, Inc.
Buntanetap is described as an orally administered small molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$95.87M |
$4.94
+2.49%
|
|
RPTX
Repare Therapeutics Inc.
RP-1664 is an oral small-molecule PLK4 inhibitor, indicating a major product category of oral small-molecule therapeutics.
|
$94.94M |
$2.20
+3.77%
|
|
PRLD
Prelude Therapeutics Incorporated
Lead programs include oral small-molecule degraders (e.g., SMARCA2 degraders, KAT6A degrader, CDK9 inhibitor), classifying them under Oral Small Molecule Therapeutics.
|
$94.52M |
$1.67
+5.03%
|
|
CRVO
CervoMed Inc.
Neflamapimod is an orally administered, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$91.97M |
$9.98
+3.69%
|
|
VTVT
vTv Therapeutics Inc.
Cadisegliatin is an oral, small-molecule therapeutic developed by the company for Type 1 Diabetes, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$86.25M |
$27.40
-1.72%
|
|
BYSI
BeyondSpring Inc.
Plinabulin is a small-molecule therapeutic; categorize under Oral Small Molecule Therapeutics.
|
$84.29M |
$2.11
+6.57%
|
|
FBIO
Fortress Biotech, Inc.
Emrosi is a modified-release oral antibiotic (minocycline), placing Fortress in the Oral Small Molecule Therapeutics category via its portfolio.
|
$82.12M |
$2.77
+2.79%
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Oral Small Molecule Therapeutics: ACR-368 and ACR-2316 are oral small-molecule inhibitors (CHK1/CHK2 and WEE1/PKMYT1).
|
$74.24M |
$2.35
+1.08%
|
|
CRDL
Cardiol Therapeutics Inc.
CardiolRx is an oral small-molecule therapeutic.
|
$72.30M |
$1.03
|
|
MNOV
MediciNova, Inc.
MN-166 (ibudilast) and MN-001 (tipelukast) are oral small-molecule therapeutics in MediciNova's development pipeline.
|
$71.12M |
$1.45
-4.61%
|
|
IFRX
InflaRx N.V.
INF904 is an oral small-molecule C5aR antagonist, representing a major Oral Small Molecule Therapeutics program.
|
$70.07M |
$1.19
+0.42%
|
|
ASRT
Assertio Holdings, Inc.
Sympazan is an oral small-molecule therapeutic delivered as a film, fitting the Oral Small Molecule Therapeutics category.
|
$69.59M |
$0.72
+1.16%
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$69.15M |
$0.70
-0.68%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$63.67M |
$1.06
+3.40%
|
|
EQ
Equillium, Inc.
EQ302 is described as an oral, bispecific inhibitor, fitting the Oral Small Molecule Therapeutics category.
|
$60.69M |
$1.01
+8.63%
|
|
ALGS
Aligos Therapeutics, Inc.
Aligos develops oral small-molecule therapeutics across its pipeline (HBV CAM-E, THR-β agonist, and pan-coronavirus protease inhibitor).
|
$60.65M |
$9.94
+2.90%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
KRON
Kronos Bio, Inc.
The company's lead assets are small-molecule therapeutics (e.g., istisociclib), indicating a focus on Oral Small Molecule Therapeutics.
|
$53.65M |
$0.88
|
|
ANL
Adlai Nortye Ltd.
The company’s pipeline includes oral small-molecule therapeutics (e.g., AN4005, AN9025), aligning with the Oral Small Molecule Therapeutics category.
|
$50.87M |
$1.37
-1.44%
|
|
KPTI
Karyopharm Therapeutics Inc.
Selinexor is an oral small molecule therapeutic; the company emphasizes oral regimens and late-stage oral therapies in MF and EC, constituting a major product category.
|
$48.13M |
$5.54
+1.74%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRX-101 is an oral small-molecule therapeutic (D-cycloserine + lurasidone) for bipolar depression.
|
$46.11M |
$2.35
+7.80%
|
|
GRCE
Grace Therapeutics, Inc.
GTx-102.00 is a betamethasone oral-mucosal spray, representing an oral small-molecule therapeutic asset.
|
$44.39M |
$3.20
|
|
TELO
Telomir Pharmaceuticals, Inc. Common Stock
Telomir-1 is described as an oral small molecule therapeutic candidate, directly matching the 'Oral Small Molecule Therapeutics' tag.
|
$42.61M |
$1.33
+1.91%
|
|
JUNS
Jupiter Neurosciences, Inc.
Direct product category: orally administered small-molecule therapeutics based on a resveratrol platform (JOTROL).
|
$42.15M |
$1.22
+3.39%
|
|
XFOR
X4 Pharmaceuticals, Inc.
Mavorixafor is an oral small-molecule therapeutic agent.
|
$41.53M |
$3.65
-3.95%
|
|
LTRN
Lantern Pharma Inc.
LP-300, LP-184, LP-284 are small-molecule oncology therapeutics candidates, aligning with the oral small molecule therapeutics category.
|
$41.04M |
$3.79
-1.04%
|
|
ATHE
Alterity Therapeutics Limited
ATH434 is a small-molecule oral therapeutic in clinical development (Phase 2) for neurodegenerative disease, identified as Alterity's lead product.
|
$40.22M |
N/A
|
Showing page 2 of 3 (254 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
